Literature DB >> 3131421

Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.

J J Stern1, M J Oca, B Y Rubin, S L Anderson, H W Murray.   

Abstract

In contrast to euthymic (nu/+) BALB/c mice, athymic nude (nu/nu) BALB/c mice fail to control the visceral intracellular replication of Leishmania donovani, do not generate the macrophage-activating lymphokine IFN-gamma, and show little or no granulomatous tissue response. To characterize the T cell requirement for successful defense against L. donovani, nude mice were first reconstituted with unfractionated nu/+ immune spleen cells, which readily conferred the capacity to control and eliminate visceral (hepatic) L. donovani. In reconstituted mice, acquired resistance was paralleled by the ability of spleen cells to generate high levels of leishmanial Ag-stimulated IFN-gamma and the development of well formed liver granulomas. In contrast, nude mice reconstituted with either L3T4+- or Lyt-2+-enriched immune spleen cells alone failed to control visceral parasite replication and did not develop effective granulomas despite the finding that transfer of L3T4+ cells largely and Lyt-2+ cells partially restored the capacity to secrete IFN-gamma. To determine whether both T cell subsets were also required in a normal host, nu/+ BALB/c mice were treated with cell-depleting anti-L3T4 and anti-Lyt-2 mAb. Depletion of either T cell subset inhibited the acquisition of resistance to L. donovani and impaired the tissue granulomatous response. Thus, successful T cell-dependent host defense towards intracellular L. donovani and the tissue expression (granulomas) of this mechanism appear to require both L3T4+ and Lyt-2+ cells. A primary role for the L3T4+ cell may be IFN-gamma production; the role of the Lyt-2+ cell and the precise interaction of the two T cell subsets remain to be identified.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131421

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  69 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

4.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

5.  Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

Authors:  P C Melby; G B Ogden; H A Flores; W Zhao; C Geldmacher; N M Biediger; S K Ahuja; J Uranga; M Melendez
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Parasite exposure elicits a preferential T-cell response involved in protective immunity against Eimeria species in chickens primed by an internal-image anti-idiotypic antibody.

Authors:  B S Bhogal; E B Jacobson; H Y Tse; D M Schmatz; O J Ravino
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

7.  Characterization of protective T cells in the acquired response to Leishmania donovani in genetically determined cure (H-2b) and noncure (H-2d) mouse strains.

Authors:  O M Ulczak; E Ghadirian; E Skamene; J M Blackwell; P A Kongshavn
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

8.  The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation.

Authors:  Susanna S Ng; Fabian De Labastida Rivera; Juming Yan; Dillon Corvino; Indrajit Das; Ping Zhang; Rachel Kuns; Shashi Bhushan Chauhan; Jiajie Hou; Xian-Yang Li; Teija C M Frame; Benjamin A McEnroe; Eilish Moore; Jinrui Na; Jessica A Engel; Megan S F Soon; Bhawana Singh; Andrew J Kueh; Marco J Herold; Marcela Montes de Oca; Siddharth Sankar Singh; Patrick T Bunn; Amy Roman Aguilera; Mika Casey; Matthias Braun; Nazanin Ghazanfari; Shivangi Wani; Yulin Wang; Fiona H Amante; Chelsea L Edwards; Ashraful Haque; William C Dougall; Om Prakash Singh; Alan G Baxter; Michele W L Teng; Alex Loukas; Norelle L Daly; Nicole Cloonan; Mariapia A Degli-Esposti; Jude Uzonna; William R Heath; Tobias Bald; Siok-Keen Tey; Kyohei Nakamura; Geoffrey R Hill; Rajiv Kumar; Shyam Sundar; Mark J Smyth; Christian R Engwerda
Journal:  Nat Immunol       Date:  2020-08-24       Impact factor: 25.606

9.  Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects Kupffer cell-restricted antigen presentation to antigen-specific CD8 T cells.

Authors:  Lynette Beattie; Adam Peltan; Asher Maroof; Alun Kirby; Najmeeyah Brown; Mark Coles; Deborah F Smith; Paul M Kaye
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

10.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.